Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9252597 | 0.84 | — | — | |
| SCHEMBL6914322 | 0.83 | — | — | |
| SCHEMBL9253410 | 0.81 | — | — | |
| SCHEMBL11962263 | 0.80 | — | — | |
| SCHEMBL6914402 | 0.80 | MAPT (0.30) | — | |
| SCHEMBL6914169 | 0.77 | NPC1 (0.32) | NPC1ALDH1A1 | |
| SCHEMBL12330747 | 0.75 | TDP1 (0.31) | — | |
| SCHEMBL6916206 | 0.72 | ALOX15 (0.32) | — | |
| SCHEMBL10107915 | 0.71 | LMNA (0.33) | — | |
| SCHEMBL6915682 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47741-E1 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-20120196791-A1 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| WO-2011044501-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2011044502-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011044503-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011044498-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011044538-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2010132760-A9 | ANTIBACTERIAL DERIVATIVES OF TOBRAMYCIN | ACHAOGEN, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2010132765-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2010147836-A9 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010147836-A1 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010132759-A1 | ANTIBACTERIAL DERIVATIVES OF DIBEKACIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132839-A2 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132760-A1 | ANTIBACTERIAL DERIVATIVES OF TOBRAMYCIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132768-A1 | ANTIBACTERIAL DERIVATIVES OF SISOMICIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132765-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132757-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010042851-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042850-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010030704-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196791-A1 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | PIGS, PIGO, NPEPPS | NPC1 465/4885ALDH1A1 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.